Background: The prevalence of macrolide-resistant Mycoplasma pneumoniae has increased considerably. Treatment in children has become challenging. This study aimed to evaluate the efficacy of doxycycline therapy for macrolide-resistant Mycoplasma pneumoniae pneumonia in children at different periods.
Methods: We retrospectively analyzed the data of patients with macrolide-resistant Mycoplasma pneumoniae pneumonia hospitalized between May 2019 to August 2022. According to treatment, patients were divided into three groups: oral doxycycline treatment alone (DOX group), changed from intravenous azithromycin to oral doxycycline (ATD group), and intravenous azithromycin treatment alone (AZI group). ATD group cases were separated into two sub-groups: intravenous azithromycin treatment<3 days (ATD1 group) and ≥ 3 days (ATD2 group). Clinical symptoms were compared in each group and adjusted by Propensity score matching (PSM) analysis.
Results: A total of 106 were recruited in this study. 17 (16%) were in DOX group, 58 (55%) in ATD group, and 31(29%) in AZI group. Compared with ATD group and AZI group, the DOX group showed shorter hospitalization duration and fever duration after treatment, while higher rate of chest radiographic improvement. After using PSM analysis, shorter days to hospitalization duration (P = 0.037) and to fever duration after treatment (P = 0.027) in DOX + ATD1 group than in ATD2 group was observed. A higher number of patients in the DOX + ATD1 group achieved defervescence within 72 h (P = 0.031), and fewer children received glucocorticoid adjuvant therapy (P = 0.002). No adverse reactions associated with doxycycline was observed during treatment.
Conclusions: Children receiving early oral doxycycline had a shorter duration of fever and hospitalization in macrolide-resistant Mycoplasma pneumoniae patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10913651 | PMC |
| http://dx.doi.org/10.1186/s13052-024-01615-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends of Mycoplasma genitalium infections in Berlin, Germany, 2017-2023.
J Glob Antimicrob Resist
December 2024
Praxis Prenzlauer Berg, Berlin, Germany.
Objectives: The cell wall-less species Mycoplasma genitalium is a sexually transmitted pathogen with strong tendency to acquire resistance. Current knowledge about trends of resistance rates and differences between the risk population of men who have sex with men (MSM) and heterosexual patients as well as about circulating genotypes in both groups is limited.
Methods: Between August 2017 and December 2023, M.
The role of macrolides in severe community-acquired pneumonia and the potential impact of macrolide-resistant Mycoplamsa pneumoniae.
Curr Opin Infect Dis
December 2024
Department of Medicine, NYP/Weill Cornell Medical Center, New York, New York, USA.
Purpose Of Review: Define the utility of adjunctive macrolide therapy in patients with more severe forms of community-acquired pneumonia (CAP).
Recent Findings: Guidelines recommend adjunctive macrolide therapy as an option for patients with CAP, admitted to the hospital. A large data set collected both retrospectively and prospectively, including several recent randomized controlled trials (RCTs) have shown that adjunctive macrolide therapy can reduce mortality and improve outcomes in patients with severe CAP, more effectively than other alternative therapies.
The association between antimicrobial resistance mutations and treatment outcomes for infections from 2018 to 2022: a cross-sectional study from Auckland, New Zealand.
Sex Health
December 2024
Virology and Immunology Department, LabPlus, Auckland City Hospital, Auckland, New Zealand.
Background New Zealand has among the highest rates of antimicrobial resistance in Mycoplasma genitalium in the world. The aim of this study was to correlate treatment outcomes with 23S rRNA and parC mutations associated with macrolide and fluroquinolone resistance, respectively, in a cohort of sexual health clinic patients. Methods Laboratory and clinical data were collected for patients with M.
View Article and Find Full Text PDFMassive Deep Venous Thrombosis in a Child with Necrotizing Pneumonia Due to Mycoplasma Pneumonia Infection.
Infect Drug Resist
November 2024
Department of Infectious Disease, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, Zhejiang, People's Republic of China.
Article Synopsis
- * An 8-year-old boy with macrolide-resistant pneumonia developed thrombosis in critical areas, including the pulmonary artery and larger veins, leading to abdominal pain and dangerous thrombi sizes.
- * After standard anti-infection and anticoagulation treatments failed to alleviate his symptoms and manage the risk of thrombus detachment, the patient underwent specialized procedures that successfully improved his condition and prevented recurrence, underscoring the importance of early thrombosis recognition in pediatric cases.
[Analysis of multidrug resistance gene locus mutations and clinical significance in children with pneumonia].
Zhongguo Dang Dai Er Ke Za Zhi
November 2024
Hubei Maternal and Child Health Care Hospital, Wuhan 430016, China.
Objectives: To detect multidrug resistance gene locus mutations in children with pneumonia through targeted high-throughput sequencing and to explore its clinical significance.
Methods: A retrospective analysis was conducted on the clinical data of 2 899 children with pneumonia, who underwent respiratory pathogen-targeted high-throughput sequencing, treated at Hubei Maternal and Child Health Care Hospital between January and December 2023. The patients were divided into a mutation group (=885) and a non-mutation group (=2 014) based on whether there was a mutation in the 23SrRNA macrolide-resistant gene of .
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!